Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Sells $28,480.75 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Patrick Lamy sold 925 shares of Akero Therapeutics stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $30.79, for a total value of $28,480.75. Following the completion of the transaction, the vice president now directly owns 17,858 shares in the company, valued at $549,847.82. This represents a 4.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Akero Therapeutics Stock Down 4.3 %

NASDAQ:AKRO traded down $1.32 during trading hours on Thursday, hitting $29.03. 332,877 shares of the company’s stock traded hands, compared to its average volume of 844,207. The stock’s fifty day moving average price is $30.77 and its two-hundred day moving average price is $26.99. The firm has a market cap of $2.03 billion, a P/E ratio of -7.74 and a beta of -0.23. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. Akero Therapeutics, Inc. has a twelve month low of $15.32 and a twelve month high of $37.00.

Akero Therapeutics (NASDAQ:AKRO) last issued its earnings results on Friday, November 8th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.15). On average, research analysts expect that Akero Therapeutics, Inc. will post -3.96 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Akero Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. grew its holdings in Akero Therapeutics by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company’s stock valued at $71,000 after purchasing an additional 446 shares during the last quarter. Eastern Bank acquired a new stake in Akero Therapeutics during the third quarter worth about $100,000. Summit Financial Wealth Advisors LLC acquired a new position in shares of Akero Therapeutics in the third quarter valued at $205,000. Victory Capital Management Inc. bought a new stake in Akero Therapeutics in the third quarter valued at about $211,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Akero Therapeutics during the 3rd quarter worth approximately $265,000.

Analyst Upgrades and Downgrades

AKRO has been the subject of several analyst reports. HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Akero Therapeutics in a research note on Monday, November 18th. Citigroup initiated coverage on Akero Therapeutics in a report on Monday, November 18th. They issued a “buy” rating and a $65.00 price target for the company. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $46.83.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.